MIM
HRMY icon

Macroview Investment Management’s Harmony Biosciences HRMY Stock Holding History

Macroview Investment Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-294
Closed -$10.3K – 833
2023
Q2 		$10.3K Buy
+294
New +$10.2K 0.02% 268

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Macroview Investment Management's HRMY Position: Q3 2023 in Review

Macroview Investment Management sold out of Harmony Biosciences (HRMY) in Q3 2023, closing a stake of 294 shares — an estimated $10.3K sold.

Macroview Investment Management first reported a position in HRMY in Q2 2023 and held it in 1 quarter. The position peaked at $10.3K in Q2 2023. 204 funds tracked by Wall St. Rank hold HRMY as of Q3 2023.

  • Macroview Investment Management reported no remaining Harmony Biosciences position as of Q3 2023 after selling out during the quarter.
  • Macroview Investment Management sold 294 Harmony Biosciences shares in Q3 2023, an estimated $10.3K.
  • Macroview Investment Management first reported a position in Harmony Biosciences in Q2 2023 and held it in 1 quarter.
  • Macroview Investment Management's Harmony Biosciences position peaked at $10.3K in Q2 2023.
  • 204 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2023.

Based on Macroview Investment Management's 13F filing for Q3 2023, filed 26 Oct 2023.